Duloxetine

Speaker 1…and this is where duloxetine, an SNRI, enters the picture. It’s used for conditions like neuropathic pain, fibromyalgia, and osteoarthritis. The thinking is that chronic pain itself is a stressor, accelerating biological aging.

Speaker 2Exactly. A study in GeroScience (2025) found that painful diabetic neuropathy is associated with accelerated epigenetic aging and telomere shortening compared with painless neuropathy. So, treating pain could theoretically slow down this aging process.

Speaker 1That’s the hope, and for many, duloxetine provides significant relief, improving quality of life. But when we look at the direct evidence for duloxetine’s impact on biological aging or all-cause mortality, the picture gets murkier.

Speaker 2It does. While managing pain is crucial, the long-term effects of duloxetine on these specific longevity markers aren't established. We don't have robust studies showing it directly slows epigenetic aging or reduces all-cause mortality.

Speaker 1And we must consider potential long-term harms. Duloxetine can cause issues like falls, sedation, and cognitive effects, especially in older adults, which could indirectly impact health and longevity. It also has a dependence risk.

Speaker 2Right. The evidence is still evolving. While it effectively manages pain for many, we can’t yet say it’s a direct longevity intervention. It’s about balancing pain relief with potential risks, and understanding what the science does and doesn't tell us about biological aging.